Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury
1 Department of Intensive Care St. Vincent's Hospital, 41 Victoria Parade, Fitzroy, Melbourne, Victoria, 3065, Australia
2 Department of Intensive Care Medicine & Laboratory of Experimental Intensive Care and Anesthesiology, The Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
3 St Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Melbourne, Victoria, 3065
4 Department of Medicine, The University of Melbourne, Clinical Sciences Building, 29 Regent Street, Fitzroy, Melbourne, Victoria, 3065, Australia
Critical Care 2010, 14:445 doi:10.1186/cc9269
See related research by Dixon et al., http://ccforum.com/content/12/3/R64
Published: 20 October 2010First paragraph (this article has no abstract)
Previously in this journal, we published a phase 1 study of nebulized heparin in patients with acute lung injury [1]. Patients were administered heparin at doses of 50,000, 100,000, 200,000, or 400,000 U/day for 2 days, and bronchoalveolar lavage (BAL) fluid samples were taken at baseline and after the last heparin dose. The study demonstrated a trend to reduced coagulation activation (prothrombin fragments) in BAL fluid after the last dose of nebulized heparin [1].
